ProMIS Neurosciences (PMN) Research & Development (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Research & Development came in at $7.0 million in Q1 2026, up 27.57% YoY from $5.5 million in Q1 2025, and down 25.59% on a QoQ basis from $9.4 million in Q4 2025.
ProMIS Neurosciences (PMN) Research & Development (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Research & Development data on file, last reported at $7.0 million in Q1 2026.
- Quarterly Research & Development rose 27.57% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.9 million (up 149.57% YoY) and the FY2025 annual result came in at $33.4 million, up 213.78% from the prior year.
- Research & Development declined to $7.0 million in Q1 2026, from $9.4 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $9.8 million in Q3 2025 to a low of $1.0 million in Q2 2023.
- A 5-year average of $4.4 million and a median of $3.5 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development surged 467.5% — and 2023, when it tumbled 75.01%.
- Tracing PMN's Research & Development over 5 years: stood at $6.4 million in 2022, then plunged by 65.15% to $2.2 million in 2023, then soared by 94.36% to $4.3 million in 2024, then jumped by 116.62% to $9.4 million in 2025, then dropped by 25.59% to $7.0 million in 2026.
- The last three Research & Development figures came in at $7.0 million (Q1 2026), $9.4 million (Q4 2025), and $9.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - | 9.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.52 Mn |
| Mar 31, 2026 | 6.97 Mn |
| Dec 31, 2025 | 9.37 Mn |
| Sep 30, 2025 | 9.80 Mn |
| Jun 30, 2025 | 8.75 Mn |
| Mar 31, 2025 | 5.46 Mn |
| Dec 31, 2024 | 4.32 Mn |
| Sep 30, 2024 | 2.56 Mn |
| Jun 30, 2024 | 1.63 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Dec 31, 2023 | 2.23 Mn |
| Sep 30, 2023 | 1.14 Mn |
| Jun 30, 2023 | 1.01 Mn |
| Mar 31, 2023 | 3.51 Mn |
| Dec 31, 2022 | 6.38 Mn |
| Sep 30, 2022 | 4.57 Mn |
| Jun 30, 2022 | 3.23 Mn |
| Mar 31, 2022 | 1.90 Mn |
| Dec 31, 2021 | 2.85 Mn |
| Sep 30, 2021 | 805,392.00 |